Clinical Trial Search

Phase 3 N=794 Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

Atopic Dermatitis

Primary: Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16. — 131; 22 Participants — p=<0.001

LEO Pharma Results Aug 2020 1.7% serious AE View details

Phase 3 N=311 A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine

Migraine

Primary: Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 54; 56; 54; 61 participants

Eli Lilly and Company Results Aug 2020 2.3% serious AE View details

Phase 3 N=62 A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

Pediatric Immuno-Tolerant Chronic Hepatitis B

Primary: Percentage of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) at 24 Weeks Post-End of Treatment/End of Untreated Observation — 3.8; 0 Percentage of…

Hoffmann-La Roche Results Aug 2020 1.6% serious AE View details

Phase 3 N=498 Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement

Axial Psoratic Arthritis

Primary: Percentage of Participants With Response to Treatment (300 mg AIN457) as Assessed by the ASAS20 Criteria at Week 12 — 66.3; 62.9; 31.2 percentage of participants…

Novartis Pharmaceuticals Results Aug 2020 4.9% serious AE View details

Phase 3 N=1,617 Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol

ASCVD · Risk Factor, Cardiovascular · Elevated Cholesterol

Primary: Percentage Change in LDL-C From Baseline to Day 510 — -49.3; 4.2 Percent change — p=<0.0001

The Medicines Company Results Aug 2020 22.4% serious AE View details

Phase 3 N=62 Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

Prurigo Nodularis · Nodularis Prurigo · Prurigo

Primary: Change From Baseline to the Evaluation Visit (Week 10) in Itch on the 0-10 Numerical Rating Scale — 27.3; 44.4; 36.4 percentage of subjects

Trevi Therapeutics Results Aug 2020 3.2% serious AE View details

Phase 3 N=540 Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression

Covid19 · Progression

Primary: Number of Participants With Progression — 5; 11 Participants

UNICEF Results Aug 2020 0.0% serious AE View details

Phase 3 N=585 A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)

Fungal Infections · Invasive Pulmonary Aspergillosis

Primary: Percentage of Participants Who Died Through Day 42 in the Intention to Treat Population — 15.3; 20.6 Percentage of Participants — p=<.0001

Merck Sharp & Dohme LLC Results Aug 2020 60.9% serious AE View details

Phase 3 N=53 Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis

Bile Acid Synthesis Defect

Primary: Change in Atypical Urinary Bile Acid Excretion by FAB-MS (Fast-Atom-Bombardment Ionization-Mass Spectrometry) — 25; 6; 10; 10 Participants

Mirum Pharmaceuticals, Inc. Results Aug 2020 35.9% serious AE View details

Phase 3 N=203 Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

Primary: The Percentage of Participants With Treatment Success at Week 8 — 35.76; 6.98 percentage of participants

Bausch Health Americas, Inc. Results Aug 2020 1.5% serious AE View details

Phase 3 N=325 A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable

Atopic Dermatitis

Primary: Percentage of Participants With Eczema Area and Severity Index (EASI) 75 (≥75% Improvement From Baseline) at Week 16 — 29.6; 62.6; 59.1 Percentage of Participants — p=<…

Regeneron Pharmaceuticals Results Aug 2020 2.2% serious AE View details